NOVO-NORDISK A/S-SPONS ADR (NVO) Stock Price & Overview
NYSE:NVO • US6701002056
Current stock price
The current stock price of NVO is 36.04 USD. Today NVO is down by -0.99%. In the past month the price decreased by -3.77%. In the past year, price decreased by -47.99%.
NVO Key Statistics
- Market Cap
- 160.193B
- P/E
- 10.12
- Fwd P/E
- 10.55
- EPS (TTM)
- 3.56
- Dividend Yield
- 4.91%
NVO Stock Performance
NVO Stock Chart
NVO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NVO. When comparing the yearly performance of all stocks, NVO is a bad performer in the overall market: 91.33% of all stocks are doing better.
NVO Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to NVO. NVO scores excellent on profitability, but there are some minor concerns on its financial health.
NVO Earnings
On February 3, 2026 NVO reported an EPS of 6.05 and a revenue of 79.14B. The company beat EPS expectations (1.39% surprise) and beat revenue expectations (1.07% surprise).
NVO Forecast & Estimates
34 analysts have analysed NVO and the average price target is 57.95 USD. This implies a price increase of 60.8% is expected in the next year compared to the current price of 36.04.
For the next year, analysts expect an EPS growth of -3.96% and a revenue growth -4.65% for NVO
NVO Groups
Sector & Classification
NVO Financial Highlights
Over the last trailing twelve months NVO reported a non-GAAP Earnings per Share(EPS) of 3.56. The EPS increased by 1.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 33.14% | ||
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| Debt/Equity | 0.61 |
NVO Ownership
NVO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.12 | 828.496B | ||
| JNJ | JOHNSON & JOHNSON | 20.64 | 579.15B | ||
| MRK | MERCK & CO. INC. | 23.12 | 295.772B | ||
| PFE | PFIZER INC | 9.06 | 153.813B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.24 | 119.215B | ||
| ZTS | ZOETIS INC | 16.01 | 47.848B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.97 | 26.738B | ||
| VTRS | VIATRIS INC | 5.2 | 15.026B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.99 | 11.5B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.997B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.705B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.62B | ||
| CORT | CORCEPT THERAPEUTICS INC | 45.51 | 4B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVO
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Info
IPO: 1974-05-17
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880 DK
CEO: Lars Fruergaard Jorgensen
Employees: 76826
Phone: 4544448888
NOVO-NORDISK A/S-SPONS ADR / NVO FAQ
Can you describe the business of NOVO-NORDISK A/S-SPONS ADR?
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
What is the stock price of NOVO-NORDISK A/S-SPONS ADR today?
The current stock price of NVO is 36.04 USD. The price decreased by -0.99% in the last trading session.
What is the dividend status of NOVO-NORDISK A/S-SPONS ADR?
NOVO-NORDISK A/S-SPONS ADR (NVO) has a dividend yield of 4.91%. The yearly dividend amount is currently 1.8.
What is the ChartMill rating of NOVO-NORDISK A/S-SPONS ADR stock?
NVO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about NOVO-NORDISK A/S-SPONS ADR (NVO) stock?
34 analysts have analysed NVO and the average price target is 57.95 USD. This implies a price increase of 60.8% is expected in the next year compared to the current price of 36.04.
Can you provide the growth outlook for NOVO-NORDISK A/S-SPONS ADR?
The Revenue of NOVO-NORDISK A/S-SPONS ADR (NVO) is expected to decline by -4.65% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for NOVO-NORDISK A/S-SPONS ADR?
NOVO-NORDISK A/S-SPONS ADR (NVO) has a market capitalization of 160.19B USD. This makes NVO a Large Cap stock.